Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1.
about
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesHuman immunodeficiency virus type 1 pathogenesis in SCID-hu mice correlates with syncytium-inducing phenotype and viral replicationClinical isolates of measles virus use CD46 as a cellular receptor.Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolatesAdaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated regionAdoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques.Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivityStructural dynamics of HIV-1 envelope Gp120 outer domain with V3 loop.Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies.Structure-based vaccine design in HIV: blind men and the elephant?Adaptation of subtype a human immunodeficiency virus type 1 envelope to pig-tailed macaque cellsHIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1.Cellular CD44S as a determinant of human immunodeficiency virus type 1 infection and cellular tropism.Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cellsCD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1.Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptorIdentification of interdependent variables that influence coreceptor switch in R5 SHIV(SF162P3N)-infected macaques.Amino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope.Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1.Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4.Independent variation and positive selection in env V1 and V2 domains within maternal-infant strains of human immunodeficiency virus type 1 in vivoMutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies.R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switchCharacterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor.Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domainSubtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection.Coreceptor use in nonhuman primate models of HIV infection.Candidate antibody-based therapeutics against HIV-1.A model of a gp120 V3 peptide in complex with an HIV-neutralizing antibody based on NMR and mutant cycle-derived constraints.HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor.Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor.Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization.The N-linked glycan of the V3 region of HIV-1 gp120 and CXCR4-dependent multiplication of a human immunodeficiency virus type 1 lymphocyte-tropic variant.Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures.Functional evolution of the HIV-1 envelope glycoprotein 120 association site of glycoprotein 41.Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.Determinant in human immunodeficiency virus type 1 for efficient replication under cytokine-induced CD4(+) T-helper 1 (Th1)- and Th2-type conditions.The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors.Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay.
P2860
Q24561905-00C91CCA-C691-40D1-B6E5-91F559421F39Q30305454-258697C5-8E4A-4C93-88D4-5B7914AFBDF3Q33803102-3295DAD5-BB27-441A-B1B3-1702A3388605Q33844079-DC7F64C1-7439-43A4-AD21-DE4A296B23FCQ33870292-16B11A73-9BC9-4944-85BB-6B70695404EDQ33961448-006AF2A9-A1BF-4EBF-A5E1-7CBFEFE28854Q33987391-7496E24C-96ED-45A1-B57E-F0B6D73F210DQ34280044-FA6FE67A-1372-4B48-916B-29D947E5CA39Q34553676-3DB63806-EF13-4435-979C-0E44ECA5B0DAQ34987048-FBAAC0C2-E050-4D96-8110-70914928CD27Q35076897-C5A504AF-A5F1-4B4A-A740-91838C683F1DQ35173635-D09DF8F5-997A-447B-BCAB-5991463B59C9Q35839936-EF2D15E6-9F57-4320-B0C4-326759E6E813Q35840680-9FF6F05C-00FF-4492-8899-34F16190714EQ35855710-ACE02841-4983-4337-9608-21D9139B1894Q35876191-BE1A6DBC-BD82-439D-B876-0E7504FD377DQ35890867-A43F914B-13DB-47E2-A648-6450C65A28B4Q36484034-3376B753-AF04-4AF0-9247-E0992DB298B2Q36622298-A9C043B0-B5BF-4CB0-891A-7D619BD4D0A0Q36624656-ED259830-0A41-4D1F-9776-69F18264FA40Q36643604-79FD593D-3DFE-41C0-923D-1B309A00D224Q36649929-A17CA473-DF94-4AA2-847E-5153AE3175C5Q36654750-84D3806D-17CD-47D3-A2E4-AF85B3600706Q36747765-81D00B1A-DE7E-48EE-9772-87EA781CA5EDQ37145319-2A69CF2E-1DBB-4258-BFBE-334E48376518Q37333789-E2D38D2B-645E-44C1-85F4-B643BE79EB6DQ37704735-B62713D9-462F-4C62-AD50-BAE372414A39Q37834099-641B2057-3092-4536-A088-EA6A5F3BAB8DQ37998496-9A12F070-B77B-4700-862F-7B8F1CBA410BQ38315995-A44FBB41-1450-4DD6-9527-7931614DF58CQ38908745-CEF3DCCF-11AE-4ED6-ADBF-E5FBC31A501EQ38943221-E9FCDF30-7D38-4E53-86BC-5FA8B926999FQ39143639-99291B3E-2E70-4EC0-8D69-A372654BA31FQ39189758-5420DE8E-1C96-4656-95D3-151EC7FCAD9BQ39313957-D873B766-F251-4D38-A5F9-2CA799270E8FQ39365770-A4C61364-4067-4D83-B649-1E1934B0BA1CQ39485924-687ED661-4F1A-4EFF-A3C2-EA82DB971D09Q39500940-619D4E5A-CC65-4164-9CEC-49DEAAB01DB5Q39597685-B589C010-88DB-4CD1-AC3A-D15B9CC45088Q39601180-B48ADF76-5009-4561-8B0E-ED157309EA45
P2860
Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Identification of envelope V3 ...... lization sensitivity of HIV-1.
@en
Identification of envelope V3 ...... lization sensitivity of HIV-1.
@nl
type
label
Identification of envelope V3 ...... lization sensitivity of HIV-1.
@en
Identification of envelope V3 ...... lization sensitivity of HIV-1.
@nl
prefLabel
Identification of envelope V3 ...... lization sensitivity of HIV-1.
@en
Identification of envelope V3 ...... lization sensitivity of HIV-1.
@nl
P2093
P356
P1433
P1476
Identification of envelope V3 ...... lization sensitivity of HIV-1.
@en
P2093
P304
P356
10.1126/SCIENCE.1636088
P407
P577
1992-07-01T00:00:00Z